Dysphagia progression-free survival in oesophageal cancer patients treated with palliative radiation therapy

SA Journal of Oncology

 
 
Field Value
 
Title Dysphagia progression-free survival in oesophageal cancer patients treated with palliative radiation therapy
 
Creator Bhim, Nazreen Bhagaloo, Visham Hunter, Alistair Chinnery, Galya Robertson, Barbara
 
Subject Oncology; Radiation Oncology; Palliative care; Gastroenterology oesophageal cancer; locally advanced; dysphagia score; palliative radiotherapy; squamous cell cancer
Description Background: In patients with advanced oesophageal carcinoma, palliation of dysphagia is important to maintain a reasonable quality of life.Aim: To determine the dysphagia progression-free survival (DPFS) in patients with advanced oesophageal carcinoma treated with palliative radiotherapy (RT).Setting: Groote Schuur Hospital, Cape Town, between January 2015 and December 2016.Methods: The medical records of all patients with oesophageal carcinoma were reviewed, and patients who were not candidates for curative treatment and received palliative RT were selected. For these patients, the dysphagia score (DS) was recorded prior to RT, six weeks after RT and at each follow-up visit. The DPFS was calculated as the time from completion of RT to worsening of DS by ≥ 1 point or until death. Other outcomes measured were objective change in DS and survival post RT.Results: The study population comprised 84 patients. Squamous cell cancer was the primary histological subtype (93%). The median duration of DPFS after RT was 73 days, with approximately two-thirds of remaining patients able to swallow at least liquids and soft diet until death. The difference in median duration of DPFS was not statistically significant in stented versus non-stented patients (54 days vs 83 days, p = 0.224). The mean change in DS was 0.45 ± 0.89 points following RT and the post-RT survival was significantly shorter in patients with stent insertion (81 days vs 123 days, p = 0.042).Conclusion: Palliative RT can successfully be used to prolong DPFS in patients with locally advanced and metastatic squamous cell cancer of the oesophagus.
 
Publisher AOSIS
 
Contributor Groote Schuur Hospital, South Africa
Date 2021-06-30
 
Type info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion — Retrospective observational
Format text/html application/epub+zip text/xml application/pdf
Identifier 10.4102/sajo.v5i0.171
 
Source South African Journal of Oncology; Vol 5 (2021); 9 pages 2523-0646 2518-8704
 
Language eng
 
Relation
The following web links (URLs) may trigger a file download or direct you to an alternative webpage to gain access to a publication file format of the published article:

https://sajo.org.za/index.php/sajo/article/view/171/492 https://sajo.org.za/index.php/sajo/article/view/171/493 https://sajo.org.za/index.php/sajo/article/view/171/494 https://sajo.org.za/index.php/sajo/article/view/171/495
 
Coverage South Africa; Western Cape; LMIC 2015-2016 Oesophageal cancer patients, stage
Rights Copyright (c) 2021 Nazreen Bhim, Visham Bhagaloo, Alistair Hunter, Galya Chinnery, Barbara Robertson https://creativecommons.org/licenses/by/4.0
ADVERTISEMENT